Preclinical News and Research

RSS

Low levels of growth hormone may contribute to growth defects in cystic fibrosis

A new study using a pig model of cystic fibrosis (CF) suggests that low levels of a growth promoting hormone at or before birth may contribute to growth defects in patients with CF.

10 Nov 2010

Myrexis presents key preclinical findings of MPI-0485520 at ACR/ARHP meeting

Myrexis, Inc., a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today presented key preclinical findings of the Company's novel oral anti-interferon, MPI-0485520, at the 74th Annual Scientific Meeting of the American College of Rheumatology/Association of Rheumatology Health Professionals, in Atlanta, Georgia.

10 Nov 2010

Preclinical data from Idera's autoimmune and inflammatory disease program presented at 74th ACR

Idera Pharmaceuticals, Inc. today announced two presentations of preclinical data from its autoimmune and inflammatory disease program at the 74th Annual Scientific Meeting of the American College of Rheumatology (ACR) in Atlanta, Georgia. One presentation is entitled "IMO-3100, a Toll-like Receptor (TLR) Antagonist, Suppresses TLR7- and TLR9-mediated Immune Responses in Non-human Primates" (#856).

10 Nov 2010

Capstone Therapeutics third quarter net loss decreases to $2.6 million

Capstone Therapeutics, formerly OrthoLogic Corp.,, today announced financial results for the third quarter of 2010.

10 Nov 2010

Neogenix awarded $488,958.50 grant under QTDP program

Neogenix Oncology, Inc. announced today that the company has been awarded two grants totaling $488,958.50, under the Qualifying Therapeutic Discovery Project Program. The two successful applications were for the company's h16C3 therapeutic antibody development program and the diagnostic biomarker development program for both their h16C3 and NPC-1C antibodies.

10 Nov 2010

TONIX Pharmaceuticals announces Phase 2a study results of cyclobenzaprine in Fibromyalgia Syndrome

TONIX Pharmaceuticals (formerly known as Krele Pharmaceuticals), a specialty central nervous system (CNS) pharmaceutical company, announced results of a new analysis of a Phase 2a study, which previously demonstrated reduced pain, fatigue and tenderness in patients with Fibromyalgia Syndrome (FMS) following bedtime administration of very low dosage (VLD) cyclobenzaprine (CBP).

10 Nov 2010

CRi adds TRIO to Nuance multispectral imaging product family

Cambridge Research & Instrumentation, Inc. (CRi), a leader in multicolor imaging solutions for preclinical and clinical research, today announced the newest addition to the award-winning Nuance™ multispectral imaging product family for multicolor tissue and cell-based imaging. The TRIO system is compact, multipurpose and affordable, offering a simplified interface and versatile design to fit any microscope with a camera-mount.

10 Nov 2010

NeuroDerm commences enrollment in ND0801 Phase 2a clinical study of ADD/ADHD in adults

NeuroDerm, Ltd. announced today that patient enrollment has begun in a Phase 2a clinical study of ND0801, a new product for the treatment of Attention Deficit Disorder/Attention Deficit Hyperactivity Disorder (ADD/ADHD) in adults. ND0801, based on a new, proprietary combination with nicotinic actions, is being developed as a dermal patch and will be evaluated for the treatment of cognitive impairment in several disorders including Alzheimer's disease, schizophrenia and advanced Parkinson's disease, among others.

9 Nov 2010

ARIAD reports $20.4 million net loss for third quarter 2010

ARIAD Pharmaceuticals, Inc. today reported financial results for the third quarter and nine months ended September 30, 2010 and provided an update on corporate developments.

9 Nov 2010

Semafore's SF1126 for B-cell chronic lymphocytic leukemia granted FDA orphan drug designation

Semafore Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the Company's SF1126 product candidate for the treatment of B-cell chronic lymphocytic leukemia (CLL). In April 2010, the Company initiated an expansion of its ongoing Phase I clinical study into this disease setting. SF1126 is a novel peptidic prodrug that converts to LY294002, one of the most widely studied small molecule inhibitors of both phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR).

9 Nov 2010

Discovery Labs reports net operating loss of $6.2 million for third quarter 2010

Discovery Laboratories, Inc., a biotechnology company developing its novel, synthetic, peptide-containing surfactant and related aerosolization technologies as first in class therapies for severe respiratory diseases, today provides an update on key pipeline and business initiatives and a financial update for the third quarter ended September 30, 2010.

9 Nov 2010

GTx third quarter net loss decreases to $8.6 million

GTx, Inc. today reported financial results for the third quarter of 2010. The net loss for the quarter ended September 30, 2010 was $8.6 million compared with a net loss of $12.8 million for the quarter ended September 30, 2009. For the nine months ended September 30, 2010, GTx reported net income of $22.8 million compared with a net loss of $35.4 million for the same period in 2009.

9 Nov 2010

Priaxon and Technical University Munich partner to develop anti-infective agents against infectious diseases

Priaxon AG, Munich, and the University Hospital Rechts der Isar (Technical University Munich) announce their cooperation for the development of new, highly selective anti-infective agents against a novel protein target class of widely spread infectious diseases. Their joint project is supported in the framework of the top cluster support project of the German Federal Ministry of Education and Research, coordinated by BioM GmbH.

9 Nov 2010

Intercell aggregate revenues decrease 28.4% to EUR 21.1m in 9 months ended September 30, 2010

Today, Intercell AG announced its financial results for the third quarter of 2010 and presented an update on the Company's key R&D programs as well as changes to the Management Board.

9 Nov 2010

ORVACS launches ERAMUNE 01 Phase II study to decrease HIV viral reservoirs

ORVACS has launched a Phase II study designed to test the hypotheses that combination therapy with potent antiviral agents and immunomodulator can lead to a decrease in the HIV viral reservoirs and, ultimately, to eradication of the virus. The study is currently being conducted at clinical sites in France, Spain, Italy, and the United Kingdom.

9 Nov 2010

Seattle Genetics, Millennium to feature SGN-35 in two oral presentations at ASH Annual Meeting

Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited today announced that brentuximab vedotin (SGN-35) will be featured in two oral presentations at the 52nd American Society of Hematology (ASH) Annual Meeting and Exposition being held December 4-7, 2010 in Orlando, FL.

9 Nov 2010

Genta commences tesetaxel Phase 2b clinical trial as 1st-line chemotherapy for metastatic breast cancer

Genta Incorporated today announced that the Company has initiated a new Phase 2b clinical trial of tesetaxel as 1st-line chemotherapy for women with metastatic breast cancer. Tesetaxel is the leading oral taxane currently in clinical development. The new trial will be conducted at Memorial Sloan-Kettering Cancer Center, New York, NY and at the Accelerated Community Oncology Research Network (ACORN) based in Memphis, TN.

9 Nov 2010

Merrimack receives $2.44 million under QTDP program to support cancer research

Merrimack Pharmaceuticals was awarded $2.44 million to support research on 10 of its cancer programs through the Qualifying Therapeutic Discovery Project, a grant program created as part of the Patient Protection and Affordable Care Act of 2010 to advance research in areas of unmet medical need.

9 Nov 2010

EpiCept third quarter net loss decreases to $3.2 million

EpiCept Corporation today announced operating and financial results for the three and nine months ended September 30, 2010, and provided an update with respect to the Company's key business initiatives.

9 Nov 2010

Soy-based drug could prevent prostate cancer metastasis

Northwestern Medicine researchers at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University have found that a new, nontoxic drug made from a chemical in soy could prevent the movement of cancer cells from the prostate to the rest of the body.

8 Nov 2010

Preclinical News and Research

Low levels of growth hormone may contribute to growth defects in cystic fibrosis

Myrexis presents key preclinical findings of MPI-0485520 at ACR/ARHP meeting

Preclinical data from Idera's autoimmune and inflammatory disease program presented at 74th ACR

Capstone Therapeutics third quarter net loss decreases to $2.6 million

Neogenix awarded $488,958.50 grant under QTDP program

TONIX Pharmaceuticals announces Phase 2a study results of cyclobenzaprine in Fibromyalgia Syndrome

CRi adds TRIO to Nuance multispectral imaging product family

NeuroDerm commences enrollment in ND0801 Phase 2a clinical study of ADD/ADHD in adults

ARIAD reports $20.4 million net loss for third quarter 2010

Semafore's SF1126 for B-cell chronic lymphocytic leukemia granted FDA orphan drug designation

Discovery Labs reports net operating loss of $6.2 million for third quarter 2010

GTx third quarter net loss decreases to $8.6 million

Priaxon and Technical University Munich partner to develop anti-infective agents against infectious diseases

Intercell aggregate revenues decrease 28.4% to EUR 21.1m in 9 months ended September 30, 2010

ORVACS launches ERAMUNE 01 Phase II study to decrease HIV viral reservoirs

Seattle Genetics, Millennium to feature SGN-35 in two oral presentations at ASH Annual Meeting

Genta commences tesetaxel Phase 2b clinical trial as 1st-line chemotherapy for metastatic breast cancer

Merrimack receives $2.44 million under QTDP program to support cancer research

EpiCept third quarter net loss decreases to $3.2 million

Soy-based drug could prevent prostate cancer metastasis

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest Life Science News